{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:29:52Z","timestamp":1793345392163,"version":"4.5.0"},"reference-count":46,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Emergency department (ED)\u2013initiated buprenorphine for the treatment of opioid use disorder (OUD) is underused.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate whether provision of ED-initiated buprenorphine with referral for OUD increased after implementation facilitation (IF), an educational and implementation strategy.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This multisite hybrid type 3 effectiveness-implementation nonrandomized trial compared grand rounds with IF, with pre-post 12-month baseline and IF evaluation periods, at 4 academic EDs. The study was conducted from April 1, 2017, to November 30, 2020. Participants were ED and community clinicians treating patients with OUD and observational cohorts of ED patients with untreated OUD. Data were analyzed from July 16, 2021, to July 14, 2022.<\/jats:p><\/jats:sec>Exposure<\/jats:title>A 60-minute in-person grand rounds was compared with IF, a multicomponent facilitation strategy that engaged local champions, developed protocols, and provided learning collaboratives and performance feedback.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcomes were the rate of patients in the observational cohorts who received ED-initiated buprenorphine with referral for OUD treatment (primary implementation outcome) and the rate of patients engaged in OUD treatment at 30 days after enrollment (effectiveness outcome). Additional implementation outcomes included the numbers of ED clinicians with an X-waiver to prescribe buprenorphine and ED visits with buprenorphine administered or prescribed and naloxone dispensed or prescribed.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 394 patients were enrolled during the baseline evaluation period and 362 patients were enrolled during the IF evaluation period across all sites, for a total of 756 patients (540 [71.4%] male; mean [SD] age, 39.3 [11.7] years), with 223 Black patients (29.5%) and 394 White patients (52.1%). The cohort included 420 patients (55.6%) who were unemployed, and 431 patients (57.0%) reported unstable housing. Two patients (0.5%) received ED-initiated buprenorphine during the baseline period, compared with 53 patients (14.6%) during the IF evaluation period (P<\/jats:italic>\u2009&amp;lt;\u2009.001). Forty patients (10.2%) were engaged with OUD treatment during the baseline period, compared with 59 patients (16.3%) during the IF evaluation period (P<\/jats:italic>\u2009=\u2009.01). Patients in the IF evaluation period who received ED-initiated buprenorphine were more likely to be in treatment at 30 days (19 of 53 patients [35.8%]) than those who did not 40 of 309 patients (12.9%; P<\/jats:italic>\u2009&amp;lt;\u2009.001). Additionally, there were increases in the numbers of ED clinicians with an X-waiver (from 11 to 196 clinicians) and ED visits with provision of buprenorphine (from 259 to 1256 visits) and naloxone (from 535 to 1091 visits).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this multicenter effectiveness-implementation nonrandomized trial, rates of ED-initiated buprenorphine and engagement in OUD treatment were higher in the IF period, especially among patients who received ED-initiated buprenorphine.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03023930<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.5439","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T15:05:38Z","timestamp":1680707138000},"page":"e235439","source":"Crossref","is-referenced-by-count":47,"title":["Implementation Facilitation to Promote Emergency Department\u2013Initiated Buprenorphine for Opioid Use Disorder"],"prefix":"10.1001","volume":"6","author":[{"given":"Gail","family":"D\u2019Onofrio","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Jennifer","family":"Edelman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn F.","family":"Hawk","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek C.","family":"Chawarski","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Pantalon","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia H.","family":"Owens","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shara H.","family":"Martel","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rothman","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustapha","family":"Saheed","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Friends Research Institute, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Cowan","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Richardson","sequence":"additional","affiliation":[{"name":"Institute for Health Equity Research, Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Salsitz","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Lyons","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio"},{"name":"Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Freiermuth","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Cincinnati, Cincinnati, Ohio"},{"name":"Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Wilder","sequence":"additional","affiliation":[{"name":"Center for Addiction Research, University of Cincinnati College of Medicine, Cincinnati, Ohio"},{"name":"Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Whiteside","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, University of Washington School of Medicine, Seattle,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith I.","family":"Tsui","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared W.","family":"Klein","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edouard","family":"Coupet","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick G.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail G.","family":"Matthews","sequence":"additional","affiliation":[{"name":"The Emmes Company, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[{"name":"Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Huntley","sequence":"additional","affiliation":[{"name":"National Institute on Drug Abuse, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Fiellin","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut"},{"name":"Yale School of Public Health, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"9","key":"zoi230190r2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.15585\/mmwr.mm6709e1","article-title":"Vital signs: trends in emergency department visits for suspected opioid overdoses\u2014United States, July 2016\u2013September 2017.","volume":"67","author":"Vivolo-Kantor","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"2","key":"zoi230190r3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.annemergmed.2021.03.013","article-title":"Emergency department visits for nonfatal opioid overdose during the COVID-19 pandemic across six US health care systems.","volume":"79","author":"Soares","year":"2022","journal-title":"Ann Emerg Med"},{"issue":"4","key":"zoi230190r4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1001\/jamapsychiatry.2020.4402","article-title":"Trends in US emergency department visits for mental health, overdose, and violence outcomes before and during the COVID-19 pandemic.","volume":"78","author":"Holland","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"zoi230190r6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103786","article-title":"Has the treatment gap for opioid use disorder narrowed in the U.S.: a yearly assessment from 2010 to 2019\u201d.","volume":"110","author":"Krawczyk","year":"2022","journal-title":"Int J Drug Policy"},{"issue":"3","key":"zoi230190r7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"issue":"1","key":"zoi230190r8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.annemergmed.2019.04.020","article-title":"One-year mortality of patients after emergency department treatment for nonfatal opioid overdose.","volume":"75","author":"Weiner","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"11","key":"zoi230190r9","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/acem.v27.11","article-title":"Emergency department\u2013initiated interventions for patients with opioid use disorder: a systematic review.","volume":"27","author":"Kaczorowsk","year":"2020","journal-title":"Acad Emerg Med"},{"issue":"16","key":"zoi230190r10","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","article-title":"Emergency department\u2013initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial.","volume":"313","author":"D\u2019Onofrio","year":"2015","journal-title":"JAMA"},{"issue":"10","key":"zoi230190r11","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.21209","article-title":"Trends in the use of buprenorphine in US emergency departments, 2002-2017.","volume":"3","author":"Rhee","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi230190r12","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.ajem.2019.02.025","article-title":"Barriers and facilitators for emergency department initiation of buprenorphine: a physician survey.","volume":"37","author":"Lowenstein","year":"2019","journal-title":"Am J Emerg Med"},{"issue":"2","key":"zoi230190r13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.5811\/westjem","article-title":"Emergency department clinicians\u2019 attitudes toward opioid use disorder and emergency department-initiated buprenorphine treatment: a mixed-methods study.","volume":"21","author":"Im","year":"2020","journal-title":"West J Emerg Med"},{"issue":"3","key":"zoi230190r14","doi-asserted-by":"publisher","DOI":"10.1002\/aet2.v6.3","article-title":"Resident attitudes, experiences, and preferences on initiating buprenorphine in the emergency department: a national survey.","volume":"6","author":"Yu","year":"2022","journal-title":"AEM Educ Train"},{"issue":"10","key":"zoi230190r15","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1016\/j.ajem.2020.03.050","article-title":"Clinician experience of nudges to increase ED OUD treatment.","volume":"38","author":"Martin","year":"2020","journal-title":"Am J Emerg Med"},{"issue":"2","key":"zoi230190r16","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ajem.2019.158373","article-title":"Evaluation of an emergency department buprenorphine induction and medication-assisted treatment referral program.","volume":"38","author":"Kaucher","year":"2020","journal-title":"Am J Emerg Med"},{"issue":"4","key":"zoi230190r17","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1017\/cem.2019.24","article-title":"Buprenorphine\/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers.","volume":"21","author":"Hu","year":"2019","journal-title":"CJEM"},{"key":"zoi230190r18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jsat.2020.02.007","article-title":"Implementation of emergency department-initiated buprenorphine for opioid use disorder in a rural southern state.","volume":"112S","author":"Bogan","year":"2020","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"zoi230190r19","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/ADM.0000000000000875","article-title":"Emergency department-initiated buprenorphine and referral to follow-up addiction care: a program description.","volume":"16","author":"Regan","year":"2022","journal-title":"J Addict Med"},{"key":"zoi230190r20","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1016\/j.annemergmed.2021.09.253","article-title":"Are emergency department patients started on medications for opioid use disorder when admitted?","volume":"78","author":"Jennings","year":"2021","journal-title":"Ann Emerg Med"},{"issue":"6","key":"zoi230190r21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1017\/cem.2020.438","article-title":"Multi-site intervention to improve emergency department care for patients who live with opioid use disorder: a quantitative evaluation.","volume":"22","author":"McLane","year":"2020","journal-title":"CJEM"},{"key":"zoi230190r22","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1007\/s11606-014-3027-2","article-title":"Outcomes of a partnered facilitation strategy to implement primary care-mental health.","volume":"29","author":"Kirchner","year":"2014","journal-title":"J Gen Intern Med"},{"issue":"1","key":"zoi230190r23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13012-019-0891-5","article-title":"Implementation facilitation to promote emergency department-initiated buprenorphine for opioid use disorder: protocol for a hybrid type III effectiveness-implementation study (Project ED HEALTH).","volume":"14","author":"D\u2019Onofrio","year":"2019","journal-title":"Implement Sci"},{"issue":"5","key":"zoi230190r24","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.4561","article-title":"Barriers and facilitators to clinician readiness to provide emergency department\u2013initiated buprenorphine.","volume":"3","author":"Hawk","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi230190r25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1748-5908-4-38","article-title":"Organizational readiness to change assessment (ORCA): development of an instrument based on the Promoting Action on Research in Health Services (PARIHS) framework.","volume":"4","author":"Helfrich","year":"2009","journal-title":"Implement Sci"},{"key":"zoi230190r26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13012-016-0398-2","article-title":"PARIHS revisited: from heuristic to integrated framework for the successful implementation of knowledge into practice.","volume":"11","author":"Harvey","year":"2016","journal-title":"Implement Sci"},{"key":"zoi230190r27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1748-5908-6-99","article-title":"A guide for applying a revised version of the PARIHS framework for implementation.","volume":"6","author":"Stetler","year":"2011","journal-title":"Implement Sci"},{"issue":"3","key":"zoi230190r30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jama.2021.9941","article-title":"Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 Statement.","volume":"326","author":"Orkin","year":"2021","journal-title":"JAMA"},{"key":"zoi230190r31","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.934514","article-title":"Editorial: reporting clinical trials with important modifications due to extenuating circumstances, including the COVID-19 Pandemic: CONSERVE 2021.","volume":"27","author":"Parums","year":"2021","journal-title":"Med Sci Monit"},{"issue":"5","key":"zoi230190r33","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.annemergmed.2022.05.010","article-title":"Models for Implementing emergency department\u2013initiated buprenorphine with referral for ongoing medication treatment at emergency department discharge in diverse academic centers.","volume":"80","author":"Whiteside","year":"2022","journal-title":"Ann Emerg Med"},{"key":"zoi230190r34","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3928\/0048-5713-20020901-06","article-title":"The PHQ-9: a new depression diagnostic and severity measure.","volume":"32","author":"Kroenke","year":"2002","journal-title":"Psych Ann"},{"issue":"1","key":"zoi230190r35","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44955","article-title":"Perspectives about emergency department care encounters among adults with opioid use disorder.","volume":"5","author":"Hawk","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi230190r36","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.annemergmed.2021.04.023","article-title":"Consensus recommendations on the treatment of opioid use disorder in the emergency department.","volume":"78","author":"Hawk","year":"2021","journal-title":"Ann Emerg Med"},{"key":"zoi230190r37","first-page":"S8","article-title":"Nationwide assessment of emergency department capabilities for patients with opioid use disorder during the COVID-19 pandemic.","volume":"29","author":"Hawk","year":"2022","journal-title":"Acad Emerg Med"},{"issue":"20","key":"zoi230190r38","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/archinternmed.2010.381","article-title":"Trends in door-to-balloon time and mortality in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.","volume":"170","author":"Flynn","year":"2010","journal-title":"Arch Intern Med"},{"key":"zoi230190r41","doi-asserted-by":"publisher","first-page":"f657","DOI":"10.1136\/bmj.f657","article-title":"Features of effective computerised clinical decision support systems: meta-regression of 162 randomised trials.","volume":"346","author":"Roshanov","year":"2013","journal-title":"BMJ"},{"key":"zoi230190r42","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069271","article-title":"User centered clinical decision support to implement initiation of buprenorphine for opioid use disorder in the emergency department: EMBED pragmatic cluster randomized controlled trial.","volume":"377","author":"Melnick","year":"2022","journal-title":"BMJ"},{"key":"zoi230190r43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/00952990.2022.2106574","article-title":"Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection.","volume":"26","author":"Hassman","year":"2022","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"6","key":"zoi230190r45","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.annemergmed.2021.05.024","article-title":"Rapid adoption of low-threshold buprenorphine treatment at California emergency departments participating in the CA bridge program.","volume":"78","author":"Snyder","year":"2021","journal-title":"Ann Emerg Med"},{"issue":"3","key":"zoi230190r46","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.annemergmed.2021.10.012","article-title":"Sustained implementation of a multicomponent strategy to increase emergency department\u2013initiated interventions for opioid use disorder.","volume":"79","author":"Lowenstein","year":"2022","journal-title":"Ann Emerg Med"},{"key":"zoi230190r1","first-page":"12","volume-title":"Provisional Drug Overdose Death Counts","author":"Ahmad","year":"2021"},{"key":"zoi230190r5","volume-title":"Medications for Opioid Use Disorder Save Lives","author":"National Academies of Sciences, Engineering, and Medicine","year":"2019"},{"key":"zoi230190r28","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"zoi230190r29","volume-title":"The ASAM criteria","author":"Mee-Lee","year":"2013"},{"key":"zoi230190r32","doi-asserted-by":"crossref","DOI":"10.1002\/0471722146","volume-title":"Applied Logistic Regression","author":"Hosmer","year":"2000","edition":"2nd ed"},{"key":"zoi230190r39","unstructured":"MDCalc. Emergency department\u2013initiated buprenorphine for opioid use disorder (EMBED). Accessed January 31, 2022. https:\/\/www.mdcalc.com\/emergency-department-initiated-buprenorphine-opioid-use-disorder-embed."},{"key":"zoi230190r40","unstructured":"Amston Studio. Buprenorphine initiation app. Accessed July 21, 2022. https:\/\/apps.apple.com\/us\/app\/bup-initiation\/id1574350314"},{"key":"zoi230190r44","unstructured":"US Department of Justice, Drug Enforcement Administration, Diversion Control Division. Elimination of the DATA waiver program. Accessed January 12, 2023. https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/index.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2803122\/donofrio_2023_oi_230190_1679930197.96211.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T15:05:49Z","timestamp":1680707149000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2803122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.5439","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]}}}